graham74GC Profile Banner
Graham Collins Profile
Graham Collins

@graham74GC

Followers
17K
Following
11K
Media
2K
Statuses
9K

Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.

Opinions are mine
Joined December 2013
Don't wanna be here? Send us removal request.
@graham74GC
Graham Collins
9 days
A real pleasure to spend the last 2 days with friends and colleagues from the Sri Lanka College of Haematology. Humbling to hear the challenges they face and inspiring to see their dedication to patient care.
2
1
31
@graham74GC
Graham Collins
9 days
Very interesting data which will go into the ongoing debate of how best to treat double hit lymphoma. #lymsm
@CwynKate
Kate Cwynarski
11 days
Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology | Blood Advances | American Society of Hematology
1
3
36
@DrCarlaCasulo
Carla Casulo, MD
18 days
Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy? https://t.co/rFW0XwVqPT Wonderful to work with Dr Laurie Sehn on this review highlighting our approach to relapsed FL #lymsm @BloodPortfolio @WilmotCancer
Tweet card summary image
ashpublications.org
Although there have been many therapeutic advances in follicular lymphoma (FL) in recent years, important questions remain about how best to integrate emer
0
14
51
@graham74GC
Graham Collins
10 days
Neelapu - long term zuma5 FU, axi-cel in iNHL (mainly FL) • 159 pts, 5y FU • 75% CRR, median PFS 62.2mo • NRM 15% • ongoing response correlated with enriched naive T-cells in axi-cel product. #lymsm https://t.co/1Dh5HzRimp
2
12
39
@graham74GC
Graham Collins
11 days
A real honour to be at the Sri Lankan college of haematology HaemIcon 2025.
1
1
9
@tobyeyre82
Toby Eyre
17 days
▶️New #CLL @BritSocHaem UK guidelines including recommendations on I+V, A+V, Zanubrutinib, Pirtobrutinib and much more! #Lymsm #CLL British Journal of Haematology | Wiley Online Library https://t.co/1NVleN62NY
3
33
88
@tobyeyre82
Toby Eyre
23 days
Hot off the press! Lewis et al. Wonderful to see this international investigator initiated academic RCT published open access in @TheLancet today Fantastic UK+Nordic collaboration #MCL #Lymsm https://t.co/Fd3DkusXlR
Tweet card summary image
thelancet.com
To our knowledge, this is the first randomised trial in untreated mantle-cell lymphoma to demonstrate significant improvement in progression-free survival for ibrutinib–rituximab compared to immuno...
1
16
63
@graham74GC
Graham Collins
26 days
Thanks to all involved in making this course so successful.
@LymphomaAction
LymphomaAction
26 days
It's been a fantastic year for #LymphomaManagement! You can now catch up on all the presentation videos and download copies of the slides. Register for on-demand access 👉 https://t.co/LvbNrNSxM8 @graham74GC @tobyeyre82 @OxfordHaem #LymSM
1
1
12
@LymphomaAction
LymphomaAction
28 days
Lymphoma is the UK’s most common #BloodCancer. As we come to the end of #BloodCancerAwarenessMonth, let's keep talking about the symptoms. Please repost so that more people know what to look out for. Find out more 👉 https://t.co/H6E5iWzRLO #LetsTalkLymphoma #Lymphoma
1
11
12
@LymphomaAction
LymphomaAction
28 days
Professor Kim Linton will discuss marginal zone #Lymphoma in this final week of our online #LymphomaManagement course. Don't miss out and book now 👉 https://t.co/LvbNrNSxM8 @graham74GC @tobyeyre82 #LymSM #Haematology
1
2
5
@tobyeyre82
Toby Eyre
1 month
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology
Tweet card summary image
ascopubs.org
In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free...
2
22
74
@graham74GC
Graham Collins
1 month
Great to have the fantastic Beth Phillips speak on the challenging area of relapsed Hodgkin and @CwynKate give a masterful overview of T-cell lymphoma. Wish you had signed up? You still can! And hear all the talks / Q&A on playback. Don’t miss it!
@LymphomaAction
LymphomaAction
1 month
Week 2 of #LymphomaManagement kicks off tonight, continuing our engaging programme for healthcare professionals working in #Lymphoma. Booking is still open 👉 https://t.co/LvbNrNSxM8 @graham74GC @tobyeyre82 @OxfordHaem #LymSM
2
2
7
@Larvol
LARVOL
1 month
A look at key updates and trials expected in Lymphoma in 2025 Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/VJu7MflQA0 #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #Lymphoma #WorldLymphomaAwarenessDay
1
11
23
@graham74GC
Graham Collins
2 months
Fantastic to have @CwynKate speak on the weird and wonderful field of T-cell Lymphoma. Join us next week!
@LymphomaAction
LymphomaAction
2 months
#LymphomaManagement starts tonight! Professor Kate Cwynarski will cover Peripheral T-cell #Lymphoma during this online course for healthcare professionals. Still to book your place? Book now and don't miss out 👉 https://t.co/LvbNrNSxM8 @graham74GC @tobyeyre82 @CwynKate #LymSM
3
4
15
@LymphomaAction
LymphomaAction
2 months
Thank you for joining Week 1 of #LymphomaManagement! Covering High-grade non-Hodgkin #Lymphoma: diagnostics and #DLBCL, it was an evening of expertise shared! You can still book to join us for the rest of the course 👉 https://t.co/LvbNrNSxM8 @graham74GC @tobyeyre82 #LymSM
0
4
4
@beth_psaila
Beth Psaila
2 months
‼️See below terrific opportunity for a postdoc post with a leading group in Oxford, super exciting science, now being applied to myeloid malignancies! 🔥🔥👇@UniofOxford @Ludwig_Cancer @ASH_hematology @CR_UK
@marketa_tomkova
Markéta Tomková
2 months
Please share: we’re recruiting a postdoctoral fellow – applications open until September 15! To lead genomics data analysis of an exciting translational project in sAML cancer, supportive environment, and access to unique in-house technologies. https://t.co/plDpkuSAnW
0
7
15
@LymphomaAction
LymphomaAction
2 months
The online #LymphomaManagement course starts tonight! We are excited to bring healthcare professionals a programme of expert speakers in #Lymphoma to refine and refresh your knowledge. Booking is still open 👉 https://t.co/LvbNrNSxM8 @graham74GC @tobyeyre82 @OxfordHaem #LymSM
0
3
5
@graham74GC
Graham Collins
2 months
Here we go with Lymphoma Management 2026! Nearly 400 people enrolled. This week: • why is lymphoma so interesting? • integrated lymphoma diagnostics • first line treatment of DLBCL • relapsed DLBCL. Thank you to Cathy Burton, Chris Fox and Andy Davies A real feast! #lymsm
1
4
29
@graham74GC
Graham Collins
2 months
Tomorrow is the start of the new Lymphoma Management course. Sign up to watch the talks which are bang up to date, and to engage in the love Q and A.
@LymphomaAction
LymphomaAction
2 months
Our online #LymphomaManagement course for healthcare professionals starts tomorrow. Dr Beth Phillips will be talking about relapsed and refractory #HodgkinLymphoma. Book now 👉 https://t.co/LvbNrNSxM8 @graham74GC @tobyeyre82 #LymSM #Lymphoma #Haematology
2
3
12
@LymphomaAction
LymphomaAction
2 months
#Lymphoma can develop at any age – it's the UK's most common #BloodCancer. This #BloodCancerAwarenessMonth, we want to encourage conversations about lymphoma, to help raise awareness. Find out more 👉 https://t.co/qkxZeKmXnx
1
5
7